Imiquimod, a TLR-7 agonist, and anti-CD47 antibodies were delivered together on a nanoscale metal framework, leading to tumor eradication when combined with checkpoint inhibitors in a colorectal tumor model (253). Here, CD47 is linked to neoplasm.